Sodium-glucose cotransporter 2 inhibitors: nephroprotective impact on diabetic kidney disease.
CONCLUSION: The initial data suggest clinically meaningful benefits of the SGLT-2 inhibitors in diabetic patients in relevance with chronic kidney disease. Future, well-designed randomised clinical trials need to be further investigate such nephroprotective outcomes, that if confirmed could lead to new perspectives in the management of diabetic nephropathy.
PMID: 29412122 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Heart | Hematology | Sodium | Urology & Nephrology